Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2

Next Previous
Trial Profile

A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Disitamab vedotin (Primary)
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Seagen

Most Recent Events

  • 07 Feb 2025 Status changed from recruiting to active, no longer recruiting.
  • 10 Sep 2024 Study design presented at the 25th World Conference on Lung Cancer
  • 02 Feb 2024 Planned number of patients changed from 190 to 160.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top